INO - Inovio Pharmaceuticals, Inc.
| Previous Close | 4.63 |
| Open | 4.61 |
| Bid | 4.55 x 1000 |
| Ask | 4.64 x 300 |
| Day's Range | 4.58 - 4.73 |
| 52 Week Range | 3.76 - 9.86 |
| Volume | 901,967 |
| Avg. Volume | 1,303,279 |
| Market Cap | 420.852M |
| Beta | 1.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.09 |
| Earnings Date | May 8, 2018 - May 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.67 |
- GlobeNewswire•2 days ago
Market Trends Toward New Normal in Community Healthcare Trust, Delek US, Endurance International Group, Tractor Supply, TransUnion, and Inovio Pharmaceuticals — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, April 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Zacks•9 days ago
Why Is Inovio (INO) Up 6.6% Since Its Last Earnings Report?
Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Benzinga•11 days ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Facebook, Inc. (NASDAQ: FB ) stock was trading lower ...
- GlobeNewswire•11 days ago
Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS
PLYMOUTH MEETING, Pa. and OSLO, Norway, April 11, 2018-- Inovio Pharmaceuticals, Inc. and CEPI– the Coalition for Epidemic Preparedness Innovations– today announced a partnership under which Inovio will ...
- Motley Fool•16 days ago
Better Buy: Intrexon Corporation vs. Inovio Pharmaceuticals Inc.
These two biotechs are beating the market so far in 2018. But which is the better pick?
- GlobeNewswire•20 days ago
Inovio Pharmaceuticals to Present at the H.C. Wainwright Annual Global Life Sciences Conference
PLYMOUTH MEETING, Pa., April 02, 2018-- Inovio Pharmaceuticals, Inc. today announced that Dr. J. Joseph Kim, Inovio’ s President & CEO, will provide a corporate overview at the H.C. Wainwright Annual Global ...
- ACCESSWIRE•last month
Blog Exposure - Inovio Pharma Closed Collaboration Deal with ApolloBio to Develop and Commercialize VGX-3100 in Greater China
Stock Monitor: Cara Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 22, 2018 / Active-Investors.com has just released a free research report on Inovio Pharma, Inc. (NASDAQ: INO ). ...
- American City Business Journals•last month
$43M deal: Inovio finalizes restructured collaboration with Chinese biopharm firm
The agreement includes a $23M upfront payment
- GlobeNewswire•last month
Inovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China
PLYMOUTH MEETING, Pa., March 20, 2018-- Inovio Pharmaceuticals, Inc. today announced it has closed an agreement providing ApolloBio Corp. with the exclusive right to develop, manufacture and commercialize ...
- Zacks•last month
Inovio's (INO) Q4 Loss Narrower than Expected, Revenues Beat
Inovio (INO) reports a narrower-than-expected loss in Q4. Moreover, revenues also beat estimates during the period and increased year over year.
- Thomson Reuters StreetEvents•last month
Edited Transcript of INO earnings conference call or presentation 14-Mar-18 8:30pm GMT
Q4 2017 Inovio Pharmaceuticals Inc Earnings Call
- InvestorPlace•last month
Inovio Pharmaceuticals Inc (INO) Q4 Revenue Grew 3.5% Year-Over-Year
Inovio Pharmaceuticals Inc (NASDAQ:INO) reported its latest quarterly earnings results after the bell Wednesday, with revenue and earnings rising year-over-year. The pharmaceutical company announced a net loss of $21.5 million, or 24 cents per share, narrower than its year-ago loss of $26.2 million, or 35 cents per share for its fourth quarter. Inovio Pharmaceuticals reported total revenue for its fourth quarter of $8.8 million, a 3.5% gain compared to the year-ago quarter of $8.5 million.
- Associated Press•last month
Inovio reports 4Q loss
On a per-share basis, the Plymouth Meeting, Pennsylvania-based company said it had a loss of 24 cents. The drugmaker posted revenue of $8.8 million in the period. For the year, the company reported that ...
- GlobeNewswire•last month
Inovio Pharmaceuticals Reports 2017 Fourth Quarter and Year End Financial Results
PLYMOUTH MEETING, Pa., March 14, 2018-- Inovio Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2017.. Total revenue was $8.8 million and $42.2 ...
- Benzinga•last month
Earnings Preview For Inovio Pharmaceuticals
Inovio Pharmaceuticals (NASDAQ: INO ) releases its next round of earnings Wednesday. Here's Benzinga's essential guide to Inovio Pharmaceuticals' earnings report. Earnings and Revenue Wall Street analysts ...
- GlobeNewswire•last month
Inovio’s DNA Immunotherapy Demonstrates Immune Response Results Key in Treating Chronic Hepatitis B Infection
PLYMOUTH MEETING, Pa., March 14, 2018-- Inovio Pharmaceuticals, Inc. today announced that interim Phase 1 results show its DNA immunotherapy designed to treat hepatitis B virus infection was safe, well-tolerated ...
- GlobeNewswire•last month
Inovio Pharmaceuticals to Report Fourth Quarter and Year End 2017 Financial Results on March 14, 2018
PLYMOUTH MEETING, Pa., March 12, 2018-- Inovio Pharmaceuticals, Inc. announced today that it will host a conference call and live webcast to report its 2017 fourth quarter and year end financial results ...
- Zacks•2 months ago
What's in the Cards for Inovio (INO) This Earnings Season?
Inovio's (INO) most advanced pipeline candidate, VGX-3100's consistent progress might drive the stock in Q4. However, lack of an approved product in the company's portfolio is a dampener.
- GlobeNewswire•2 months ago
Market Trends Toward New Normal in Rockwell Collins, Sprouts Farmers Market, Inovio Pharmaceuticals, CVS Health, FirstEnergy, and Welbilt, Inc. — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Feb. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Rockwell ...
- American City Business Journals•2 months ago
Inovio lands $4.6M in funding for malaria, tuberculosis vaccines
Inovio Pharmaceuticals Inc. said Monday it has received $4.6 million in grant funding from the Bill & Melinda Gates Foundation and the National Institutes of Health to advance work on vaccine programs targeting tuberculosis and malaria. The Plymouth Meeting biopharmaceutical company is conducting its research as part of its partnership with the Wistar Institute of Philadelphia. Both programs involve the use of Inovio's SynCon synthetic vaccine technology that helps a person's own immune system recognize cells with antigens associated with a virus or disease.
- GlobeNewswire•2 months ago
Inovio and The Wistar Institute Receive More Than $4.6 Million in R&D Funding to Advance Vaccines Against Tuberculosis & Malaria
PLYMOUTH MEETING, Pa., Feb. 12, 2018-- Inovio Pharmaceuticals, Inc. today announced that the company is collaborating with The Wistar Institute to advance two novel SynCon ® vaccine programs against tuberculosis ...
- GlobeNewswire•2 months ago
Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences
PLYMOUTH MEETING, Pa., Feb. 05, 2018-- Inovio Pharmaceuticals, Inc. today announced that the Company will participate in the following upcoming investment conferences:. BIO CEO & Investor Conference Presentation ...
- Barrons.com•3 months ago
Inovio Drops 11% One Day After Soaring on Flu Vaccine Hopes
Things are looking up for flu sufferers and for shares of Inovio Pharmaceuticals (INO), after the Plymouth Meeting, Penn.-based firm boasted yesterday that its experimental vaccine protected lab animals from every known strain of deadly influenza. Inovio's stock has gained 16% this week on hopes for a universal flu shot that will free epidemiologists from guessing which strains to put in each season's vaccine. The appeal of a broadly-protective flu vaccine will be obvious to anyone who got sick this year after getting a vaccine that was only 30% effective against the flu strain that became prevalent.
- InvestorPlace•3 months ago
3 Stocks Under $10 That Surged Yesterday
Here at Zacks, we encourage investors to follow our proven stock-picking system, which places a great deal of emphasis on the importance of earnings estimate revisions in order to identify winning stocks. However, we also always look to cover stocks, from S&P 500 powers to small cap-firms, when they make newsworthy moves.
- Zacks•3 months ago
Inovio's Influenza Vaccine Shows Potential, Shares Rally
Inovio Pharmaceuticals' (INO) universal influenza vaccine leads to broad protective antibody responses against all major deadly strains of H1 virus.
